Recognitions, Patent Issuance, Financial Results, Upcoming Investor Conferences and Update on ClinicalTrial - Research Report on

     Recognitions, Patent Issuance, Financial Results, Upcoming Investor
  Conferences and Update on ClinicalTrial - Research Report on Stereotaxis,
          Immunomedics, Novadaq, Avanir, and Raptor Pharmaceuticals

PR Newswire

NEW YORK, October 28, 2013

NEW YORK, October 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting
Stereotaxis Inc. (NASDAQ: STXS), Immunomedics Inc. (NASDAQ: IMMU), Novadaq
Technologies Inc. (NASDAQ: NVDQ), Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR),
and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Stereotaxis Inc. Research Report

On October 23, 2013, Stereotaxis Inc. (Stereotaxis) announced that the
Ministry of Health, Labor, and Welfare (MHLW) in Japan had classified its
Niobe Magnetic Navigation System as a C2 medical device. According to
Stereotaxis, the C2 classification recognizes the Niobe system as a new,
distinctive technology with clinical benefits and is the highest of five
reimbursement categories for medical devices in Japan. The Company reported
that the MHLW has also approved reimbursement for two electrophysiology
ablation catheters compatible with Niobe magnetic navigation with effect from
October 1, 2013. Stereotaxis informed that the latest achievement marks an
important step toward more permanent reimbursement coverage of the Niobe
system in Japan. The Company stated that Japan's MHLW, will establish a more
permanent "technical fee" for procedures using the Niobe system during its
biennial review of insurance reimbursement pricing for C2 devices before April
1, 2014 and until then and with effect from October 1, 2013, MHLW has
approved a temporary "technical fee" of 343,700 yen ( c.$3,500) per Niobe
procedure. The Full Research Report on Stereotaxis Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/b071_STXS]

--

Immunomedics Inc. Research Report

On October 22, 2013, Immunomedics Inc. (Immunomedics) announced the issuance
of U.S. patent no. 8,562,988 to its subsidiary, IBC Pharmaceuticals, Inc.
(IBC), for "Novel Strategies for Improved Cancer Vaccines." Immunomedics
stated that the new patent concerns methods and compositions for forming
anti-cancer vaccine complexes created with the Company's proprietary
DOCK-AND-LOCK (DNL) method. The Company informed that the allowed claims cover
the use of bispecific antibodies targeting CD74, the major histocompatibility
complex (MHC) class-II invariant chain, Ii, of immune cells, and CD20 to form
a vaccine complex. Immunomedics added that the said patent will expire in
March 2026. Cynthia L. Sullivan, President and CEO, Immunomedics, commented,
"This is an important patent protecting a new vaccine technology targeting
dendritic cells for blood cancer treatment. This method also has the potential
of including the use of a cytokine, such as interleukin-2, interleukin-12, or
gamma-interferon." The Full Research Report on Immunomedics Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/c20d_IMMU]

--

Novadaq Technologies Inc. Research Report

On October 22, 2013, Novadaq Technologies Inc. (Novadaq) announced its Q3 2013
results. The Company reported total revenues of $8.9 million, representing an
increase of 48.6% YoY, primarily driven by continued adoption of SPY
technology procedures and higher capital system sales. Net loss stood at $6.9
million or $0.14 per diluted share in Q3 2013, compared to $9.3 million or $
0.23 per diluted share in Q3 2012. Dr. Arun Menawat, Novadaq's President and
CEO, stated, "The most notable achievement for Novadaq in the third quarter
was the sale of 31 PINPOINT, LUNA, and SPY Elite systems. We remain focused on
building our direct sales team further and continuing clinical studies to
drive adoption of our PINPOINT and LUNA systems." The Full Research Report on
Novadaq Technologies Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/3a51_NVDQ]

--

Avanir Pharmaceuticals, Inc. Research Report

On October 22, 2013, Avanir Pharmaceuticals, Inc. (Avanir) announced the
enrollment of the first patient in study AVR-133. According to Avanir, the
study is a proof of concept, Phase II clinical trial investigating the use of
AVP-923 for treating levodopa induced dyskinesia (LID) in patients with
Parkinson's disease (PD). According to the company, the said study will enroll
approximately 16 PD patients across three study centers in the US and Canada
and will compare AVP-923 (45 mg of dextromethorphan / 10 mg of quinidine) with
placebo for treatment of LID. Anthony E. Lang, MD, Professor and Director of
the Division of Neurology and Chair for Parkinson's Disease Research at the
University of Toronto, said, "Despite advances in PD therapeutics, many
patients still suffer with poorly controlled dyskinesias, especially as they
require higher doses of medications to increase dopamine levels. Dyskinesias
can not only be disabling but may also limit the dose of effective medications
that treat core symptoms of PD." Avanir informed that it expects to release
top line data for the study in H2 2014. The Full Research Report on Avanir
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2ee8_AVNR]

--

Raptor Pharmaceuticals Corp. Research Report

On October 21, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals)
announced that it will release its Q3 2013 financial results after the market
closes on Thursday, November 7, 2013. The Company informed that it will also
host a conference call to discuss its financial results and provide a
corporate update on the same day at 4:30 p.m. EST (1:30 p.m. PST). The Company
stated that the live webcast of the conference call and replay of the same
will be available through its Investor Relations website. The Full Research
Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/a001_RPTP]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.